However, to date, no thorough head-to-head comparison of the efficacy of the two modifications with respect to antisense splicing therapy in SMA mouse models has been performed, and therefore, it is unclear if one of the modifications might be more advantageous for SMA therapy. Here, SMN1 is linked to proximal spinal muscular atrophy.